Fig. 1From: Combining serum inflammation indexes at baseline and post treatment could predict pathological efficacy to anti‑PD‑1 combined with neoadjuvant chemotherapy in esophageal squamous cell carcinomaThe prediction ability of serum inflammation indexes to distinguish responders and non-responders (showing the serum inflammation indexes with relatively good prediction ability). A NLR at baseline; B LMR at baseline; C PLR at baseline; D SII at baseline; E LMR at post treatment of second period; F LMR at post treatment of third period; G PLR at post treatment of third period; H SII at post treatment of second period; I Predictive model of combining serum biomarkers; J Predictive model of combining NLR and SII at baseline; K Predictive model of combining LMR and SII at baseline; L Predictive model of combining PLR and SII at baselineBack to article page